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A B S T R A C T
Optical imaging is an emerging strategy for in vitro and in vivo visualization of the molecular mechanisms of
cancer over time. An increasing number of optical imaging contrast agents and techniques have been developed
in recent years speciﬁcally for bone research and skeletal metastases. Visualizing molecular processes in relation
to bone remodeling in metastasized cancers provides valuable information for understanding disease mechan-
isms and monitoring expression of primary molecular targets and therapeutic eﬃcacy. This review is intended to
provide an overview of tumor-speciﬁc and non-speciﬁc contrast agents in the ﬁrst near-infrared window (NIR-I)
window from 650 nm to 950 nm that can be used to study functional and structural aspects of skeletal re-
modeling of cancer in preclinical animal models. Near-infrared (NIR) optical imaging techniques, speciﬁcally
NIR spectroscopy and photoacoustic imaging, and their use in skeletal metastases will also be discussed.
Perspectives on the promises and challenges facing this exciting ﬁeld are then given.
1. Introduction
Bone is one of the most common metastatic sites of malignant
neoplasms. There are over 600,000 cases of bone metastases diagnosed
every year in the USA in older adults (> 40 years of age) [1]. Metastasis
is characterized by severe pain, pathologic fracture, spinal compression,
hypercalcemia, and ultimate mortality associated with end-stage can-
cers in breast, prostate, melanoma and multiple myeloma (MM) [2].
Advances in clinical imaging modalities have allowed for early detec-
tion of skeletal metastasis for accurate staging as well as implementa-
tion of optimal treatment strategies. While traditional modalities, such
as planar X-ray and Computed Tomography (CT), provide structural
information on calciﬁed tissue, these modalities do not provide the
functional information that is of great importance in staging metastatic
tumor growth. Single Photon Emission Computed Tomography (SPECT)
and Positron Emission Tomography (PET) are currently the gold stan-
dards in performing such noninvasive functional clinical imaging.
SPECT, particularly bone scintigraphy, as well as PET can be used to
measure tracer uptake into tissues and therapeutic eﬀects on disease
processes. While SPECT and PET are highly sensitive, there are several
limitations. In addition to the use of ionizing radiation and relatively
poor spatial resolution (through several millimeters) compared to
magnetic resonance imaging (MRI), X-ray and CT, it is only possible to
trace one molecular species with PET and does not allow for monitoring
of interactions between molecular targets [3].
In preclinical skeletal cancer research, optical imaging in the ﬁrst
near-infrared (NIR-I) window (650–950 nm) [4] is a rapidly emerging
ﬁeld, with widespread applications for functional and structural ima-
ging of the bone as well as tumors within the bone microenvironment.
These techniques not only allow for multiplexing of signals, but also for
evaluating interactions between speciﬁc molecular targets in relation to
bone growth, the microenvironment and tumor metastasis. With ad-
vances in microscopy, small animal imaging instrumentation and novel
tumor- and bone- speciﬁc contrast agents, optical imaging is a low-cost,
high-throughput method of bone imaging. While we recognize the need
for bioluminescence imaging (BLI) and ﬂuorescent reporter constructs
in the study of bone metastases, this review is focused on optical ima-
ging modalities in the NIR-I window. Here, we give an overview of NIR
optical imaging molecular probes, both commercial as well as in de-
velopment, that are used for functional imaging of biological processes
in relation to metastasized cancers to the bone. This is followed by
optical imaging techniques in the NIR-I window used to endogenously
image structural components of the bone and molecular processes in the
bone microenvironment during metastases. We conclude with a sum-
mary and an outlook of future directions in skeletal imaging and how
these various imaging techniques can be applied to characterizing bone
metastases.
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Tumor cells, bone cells, secreted factors, extracellular matrix, and
tumor–bone interactions all play crucial roles in the growth and colo-
nization of tumor cells in the bone microenvironment. This includes
activation of angiogenic signaling pathways between tumors and
stroma cells, local increases in bone turnover and osteolytic lesions, and
suppression of the adaptive immune system. All of these processes
provide a positive feedback cycle on tumor metastases [5]. Recent de-
velopments in NIR ﬂuorescent contrast agents have allowed for func-
tional imaging of these bone-related processes. NIR ﬂuorescence also
oﬀers reduced autoﬂuorescence in vivo compared to the visible ﬂuor-
escence range (400 to 650 nm) in preclinical animal models [4]. Such
noninvasive imaging allows for longitudinal evaluation of cancer-spe-
ciﬁc therapies without the need to sacriﬁce mice. Multiplexing of
ﬂuorescence signals at diﬀerent emission wavelengths provides valu-
able functional information on how diﬀerent molecular processes in-
teract with one another and where tumor cells migrate to in real-time.
Bone- and vasculature-speciﬁc NIR ﬂuorescent agents can be co-ad-
ministered to identify where tumors are growing and where biological
processes involved in metastases are occurring with respect to diﬀerent
anatomical features in vivo. Ex vivo imaging of excised tissue allows
researchers to locate where a receptor or protein of interest is expressed
on the tumor cell and simultaneously evaluate diﬀerent molecular
processes in the context of individual cells.
Despite the advantages oﬀered with NIR ﬂuorescent contrast agents,
the fundamental limitations associated with ﬂuorescent imaging need
to be considered when performing such imaging. High photon scat-
tering and tissue attenuation limit translation of these agents into hu-
mans for noninvasive imaging, particularly for skeletal imaging. While
ﬂuorescent contrast agents provide valuable functional information,
these agents do not provide the same structural or compositional in-
formation that is oﬀered by other anatomical imaging modalities.
Questions regarding tumor depth and shape, for example, are highly
dependent on the tissue scattering properties and depth of tissue [6,7],
and therefore cannot be accurately determined solely using NIR ﬂuor-
escence as compared to X-ray, CT or MR imaging. Spectral overlap
between diﬀerent ﬂuorophores also limits the number of processes that
can be evaluated at any one time. Fluorophores must be chosen such
that emission peaks are preferably 20 nm apart from one another,
limiting the potential number of contrast agents that can be adminis-
tered at any one time [8]. However, successful examples exist, such as
the work by Kobayashi et al. who demonstrated simultaneous multi-
color imaging of 5 diﬀerent NIR contrast agents in vivo [8]. With recent
advances in targeting moieties and improved technologies for real-time
ﬂuorescence imaging in small animal models, NIR ﬂuorescent agents
have pushed the ﬁeld forward and can provide valuable functional in-
formation on biological processes involved in bone metastases and as-
sociated therapies in preclinical animal models. Here, we evaluate
several tumor- and bone-speciﬁc NIR tracers as deﬁned by their primary
target (shown in Table 1 and Fig. 1).
2.1. Functional imaging of biological processes involved in bone metastases
2.1.1. Metabolism
One of the hallmarks of tumor cell development is an elevated rate
of glycolysis, even under aerobic conditions [9]. This increased demand
for glucose and subsequent increased production of cellular metabolites
leads to the recruitment of macrophages and other immune cells that
promote metastasis [10]. Aerobic glycolysis is often stimulated by on-
cogenes, such as PIK3 and Ras, which induce the upregulation of glu-
cose transporter proteins (GLUT), in particular GLUT1, and allows for
traﬃcking of glucose into the tumor cell [11]. IRDye800CW 2-DG (Li-
Cor) exploits this family of transporter proteins using the stable glucose
analog 2-deoxyglucose (2-DG) [12]. IRDye800CW is a NIR dye (Ex./
Em. 774 nm/810 nm) that exhibits deeper tissue penetration and a
higher photostability than Cyanine 5.5 (Cy5.5) (Ex./Em. 684 nm/
710 nm) due to the longer excitation wavelength [13]. IRDye800CW
can be functionalized with either an N‑hydroxy succinimide (NHS) ester
or maleimide reactive group, allowing it to be attached to a number of
biomolecules for targeting to an amide group [13].
Fluorescence microscopy conﬁrmed dose-dependent uptake of
IRDye800CW 2-DG in the cytoplasm of various tumor cell lines [12]. In
vivo studies have shown high speciﬁcity of IRDye800CW 2-DG in tumor-
bearing regions, which were veriﬁed with BLI and MRI [14]. In vivo BLI
signals were found to be linearly correlated with ﬂuorescence imaging
from IRDye800CW 2-DG [15]. In addition, areas of low oxygen con-
centration or hypoxic regions also play a role in the heterogeneous
uptake of the probe with higher uptake of IRDye800CW 2-DG observed
in hypoxic tumor regions [16]. While the molecular mechanism by
which IRDye800CW 2-DG enters the tumor cell is not entirely known, it
is believed that the GLUT/IRDye800CW 2-DG complex is endocytosed
into the cell following binding [12]. IRDye800CW 2-DG has not been
speciﬁcally studied in bony metastatic models. Despite possible uptake
of IRDye800CW 2-DG in non-speciﬁc areas of high glucose avidity, it
serves as a good potential candidate for characterizing metabolic ac-
tivity in tumor cells residing in bone both in vivo and ex vivo.
2.1.2. Adhesion
Integrin-mediated contacts with the extracellular matrix and
stromal cells play a deﬁning role in the pathogenesis of bone metas-
tases. Overexpression of integrin signaling by cancer cells further pro-
motes proliferation within the bone microenvironment [17]. The acti-
vated form of the receptor VLA-4 (Very Late Antigen-4, also known as
α4β1) plays a vital role in mediating adhesion of hematopoietic cells,
primarily MM tumoral cells, to the bone marrow (BM) stroma and
promoting tumor cell traﬃcking, proliferation and drug resistance [18].
Adhesion of VLA-4 to its targeting ligand VCAM-1, which is over-
expressed on the surface of endothelial cells, promotes bone metastases,
suggesting this interaction mediates homing of tumors to the bone [19].
LLP2A is a high-aﬃnity peptidomimetic ligand for the activated con-
formation of VLA-4. Fluorescently-conjugated LLP2A has shown pro-
mise as an imaging agent in MM, lymphoma and leukemia models
Table 1
Various optical imaging probes and their associated primary targets.
Cell type Mechanism of action Ligand Tracer Used in models of bony metastasis or intramedullary tumors? Publication
Tumors Cell metabolism GLUT Transporter IRDye800CW 2-DG No –
Adhesion factors VLA-4 LLP2A-Cy5/Cy5.5/AF680 Yes [20]
Angiogenesis Blood Pool AngioSense Yes [30,31]
Osteoclasts Hydroxyapatite OsteoSense Yes [33,36–40]
BoneTag No –
Cy5.5-iminodiacetates No –
Bone degradation MMP MMPSense No –
Cathepsin B GB123 Yes [40]
Cathepsin K CAT K FAST 680/750 Yes [36]
ProSense No –
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[20–22]. In vitro imaging of LLP2A showed speciﬁc surface binding on
α4β1 expressing tumor cells in human BM samples (Fig. 2) [20]. In vivo
imaging of LLP2A was studied in mouse xenograft models and showed
high sensitivity and speciﬁcity with fast clearance through the kidneys
[20–22]. This is a promising approach for visualizing changes in cell
adhesion-mediated tumor interactions within the bone microenviron-
ment in preclinical models.
2.1.3. Angiogenesis
The interaction of metastasized tumor cells with extracellular ma-
trix (ECM) proteins and BM cells, as well as in the BM milieu, play a
crucial role in tumor pathogenesis and drug resistance [23–25]. Tu-
mors, particularly MM tumoral cells, are characterized by widespread
involvement of the BM at diagnosis, implying circulation into the per-
ipheral blood and traﬃcking of tumor cells into new sites of the BM via
chemokines and other signaling cascades [26,27]. Methods to track
bone metastasized tumor cells, both in the BM and circulation, are
valuable for developing new therapeutic strategies to target malignant
cells in the bone microenvironment.
While angiogenesis is a critical marker of tumorigenesis, delineating
tumor masses from healthy BM solely with angiogenic markers can be
extremely challenging due to the highly vascularized nature of the BM
microenvironment [28,29]. Angiogenic-speciﬁc NIR contrast agents,
however, can be used as an anatomical marker for blood vessels in
conjunction with other tumor-speciﬁc contrast agents or tumor cells
expressing a ﬂuorescent protein. AngioSense (Perkin Elmer) has been
used in imaging BM vasculature in relation to intramedullary tumors in
MM. The agent is a ﬂuorescently-labelled, long-circulating synthetic
graft polymer conjugated to either the ﬂuorophore VivosTag680 (An-
gioSense680; Ex./Em. 680 nm/700 nm) or VivosTag750 (Angio-
Sense750; Ex./Em. 750 nm/770 nm). Runnels et al. used Angio-
Sense750 in order visualize early MM cell division along vasculature in
regions adjacent to marrow spaces. By transfecting green ﬂuorescent
protein (GFP) constructs into human myeloma cells, noninvasive in vivo
ﬂow cytometry and confocal microscopy were used to follow engraft-
ment of MM cells in the BM vasculature in immunocompromised mice.
MM cells were found closely associated with normal marrow vascu-
lature adjacent to marrow spaces inﬁltrated with tumor, suggesting that
vasculature plays a signiﬁcant role in the dissemination of the disease in
the BM [30]. Using similar imaging techniques, Azab et al. also used
AngioSense750 to image the blood vessels in the BM niches of MM
murine models. AMD3100 is a small molecule inhibitor that prevents
homing of MM cells to the BM. By multiplexing with markers for cell
viability and apoptosis in conjunction with ﬂuorescently-labelled blood
vessels, the authors could visualize apoptotic MM cells in the circula-
tion of mice treated with AMD3100 and a frontline MM therapy, bor-
tezomib [31].
2.2. Optical imaging of the skeleton and skeletal processes
2.2.1. Osteoclasts
There are two major, commercially-available NIR ﬂuorescent ima-
ging probes speciﬁc to the skeleton. Such bone-speciﬁc ﬂuorophores
may be administered in conjunction with other tumor-speciﬁc ﬂuor-
ophores in order to visualize the bone anatomy via multiplexing of
signals. By using diﬀerent ﬂuorophores of diﬀerent emission wave-
lengths, areas of metastasis in murine models can be identiﬁed in re-
lation to bone regions [32].
OsteoSense (Perkin Elmer) is one of the most commonly used pre-
clinical contrast agents for imaging the bone in vivo. OsteoSense is a
Fig. 1. Tumor to bone interactions during skeletal metastasis. Schematic of the associated factors and receptors that promote bone fractures and metastasis.
Fig. 2. Representative image of MM patient BM sample stained with
LLP2A-Cy5. LLP2A exhibited punctate staining around the cell periphery,
consistent with it labeling VLA-4. LLP2A staining is shown in green and 4′6-
diamidino-2-phenylindole (DAPI) labeling of nuclei in blue (This research was
originally published in JNM. Soodgupta, D., et al. Ex vivo and In Vivo
Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging
Agents. J Nucl Med. 2016; 57: 640–645. © SNMMI).
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ﬂuorescently-labelled bisphosphonate, a class of drugs targeting the
hydroxyapatite (HA)-active regions on the mineralized bone surface,
where they are taken up by osteoclasts [33,34]. This probe is available
with diﬀerent excitation and emission wavelengths: OsteoSense680
(Ex./Em. 680 nm/700 nm), OsteoSense750 (Ex./Em. 750 nm/780 nm)
and OsteoSense800 (Ex./Em. 780 nm/805 nm). OsteoSense has shown
strong and long-lasting speciﬁcity in vivo and has been correlated with
diﬀerential expression of HA, bone size and rate of bone remodeling
[35]. OsteoSense has shown to accumulate in areas of high bone
turnover, indicating bone lesion activity and has been used in mon-
itoring osteoclast activity in bone metastatic cancer models [33]. Pri-
mary prostate and breast cancers metastasized to the bone have been
explored using this imaging probe. Kozloﬀ et al. intratibially implanted
PC-3 cancer cells into mice to assess OsteoSense binding in a bone re-
sorption model [33]. Fluorescence Molecular Tomographic (FMT)
imaging showed increased binding in mice with severe osteolysis, but
not in mice with moderate osteolysis. Fractures were conﬁrmed via X-
ray imaging (Fig. 3A).
OsteoSense has also been used in longitudinal therapy studies in
skeletal metastatic animal models for noninvasive imaging of bone re-
formation in vivo. Gálban et al. intratibially injected MDA-MB-231
human breast cancer cells into immunocompromised mice. Following
weekly administration of the therapy docetaxel, mice were subse-
quently administered OsteoSense800 as the primary diagnostic probe to
functionally assess bone remodeling in treated and untreated groups
[36]. Progressive increases in relative OsteoSense800 signal for treated
groups compared to control groups indicated upregulated osteoblastic
activity and improved bone reformation.
Although OsteoSense has been the sole ﬂuorescent probe adminis-
tered in bone metastatic models, it can also be co-administered in
conjunction with other tumor-speciﬁc markers to visualize bone
anatomy and spatially identify where tumors are metastasizing with
respect to the bone [37–40]. Imamura et al. transplanted ﬂuorescently-
transfected human breast cancer cells in bone metastatic murine models
to visualize the cell cycle of cancer cells in vivo [38]. Intravital micro-
scopy was used to noninvasively image metastasized tumor cells in the
S/G/M2 phase in female nude mice. OsteoSense750 was co-adminis-
tered to stain for bone to visualize where tumor cells were growing in
vivo. Fluorescent visualization of the bone allowed researchers to co-
register ﬂuorescence emitted at diﬀerent wavelengths and to validate
where tumor-speciﬁc ﬂuorescence is emitting from in vivo.
While bisphosphonates have high aﬃnity for bone surfaces, these
compounds have shown to induce osteoclast-induced apoptosis, leading
to high bone turnover [41,42] and osteonecrosis [43]. This limits long-
term storage of bone tissue stained with OsteoSense. To overcome this
limitation, recent advances have been made towards peptide-based
imaging agents that are both derived from and speciﬁc to natural bone-
binding proteins. BoneTag (Li Cor BioSciences) is a tetracycline deri-
vative, conjugated to IRDye800CW as well as IRDye680 (Ex./Em.
680 nm/700 nm), that targets mineralized bone matrix as a calcium
chelator [44]. BoneTag has also been used to study osteoblastic activity
in osteoarthritis [45] as well as coronary atherosclerotic murine models
[46] due to the active expression of HA in these disease models. While
OsteoSense as well as BoneTag have shown positive correlation with
Alizarin Red S staining and reduced autoﬂuorescence in vivo, BoneTag
is more speciﬁc under conditions of low mineralization [47]. In addi-
tion, BoneTag can be stored for up to a year without losing speciﬁcity
compared to the limited storage time of 8 weeks with OsteoSense [47].
While BoneTag has yet to be tested in the presence of bone metastatic
cancers, there is great potential for skeletal imaging and measuring
osteoblastic activity in these models, particularly in the presence of
genetic modiﬁcations as well as cancer therapies speciﬁc to bone me-
tastasis. Similarly to OsteoSense, BoneTag may also be administered in
conjunction with other tumor-speciﬁc ﬂuorophores in order to identify
regions of tumor metastasis within mice (Fig. 3B).
Another class of peptides, iminodiacetates, imitate the bidentate
structure of one of the side chains of osteocalcin. Osteocalcin is a pro-
tein that binds to HA amino acid residues and is produced by osteo-
blasts during bone formation and healing. Harmatys et al. [48] and Pes
et al. [49] have demonstrated the feasibility of ﬂuorescently-conjugated
iminodiacetates for skeletal imaging in metastasized breast cancer
models. In vivo studies have shown higher uptake at 19 days with a
tetra-iminodiacetate moiety, conjugated to Cy5.5 dye, than the uptake
from OsteoSense750 while exhibiting high renal clearance from this
moiety within hours of injection [48]. While these imaging agents have
yet to be evaluated in bony metastatic models, future work with small
molecule agents or nanoprobes using a multivalent iminodiacetate
group has promise as bone targeting agents.
2.2.2. Matrix degradation
Various factors participate in the vicious cycle in which cancer cells
are stimulated to promote pro-osteolytic factors, causing bone loss and
fracture. Fluorescent approaches have emerged to image matrix de-
gradation and local inﬂammation and typically involve selective clea-
vage of ﬂuorescently-conjugated macromolecules by cathepsins or
matrix metalloproteinases (MMPs) for ﬂuorescence to be released.
These contrast agents primarily rely on self-quenching upon binding to
the target of interest. Several ﬂuorophores are in close proximity to
each other on the targeting macromolecule and the small distance be-
tween the ﬂuorophores leads to quenching of the ﬂuorescent signal.
When the ligand is enzymatically digested, the ﬂuorophores are re-
leased. The ﬂuorophores are no longer quenched and the signal can be
detected with ﬂuorescence imaging equipment.
Cathepsins are a family of proteases expressed by active osteoclasts
and are involved in the breakdown of the bone matrix. Cathepsins B
(Cat B) and K (Cat K) recruit macrophages that further promote tumor
metastases and are highly present within osteolytic lesions and sites of
osteoclastic bone resorption [50]. ProSense (Perkin Elmer) is an
Fig. 3. Representative images of osteoclast-speciﬁc ﬂuor-
escent probes in metastatic murine models. A) Mice re-
ceiving intratibial injections of PC-3 prostate cancer cells,
leading to variable degrees of osteolysis 24 days post-injec-
tion. X-ray (left) was performed to conﬁrm fractures (shown in
black arrows). In vivo FMT imaging of OsteoSense (right) re-
vealed ﬂuorescent binding in mice progressing to fracture, but
not in mice with only moderate osteolysis. Dotted lines re-
present tibial and foot outlines guided by planar ﬂuorescent
and white-light images taken before FMT scan. White arrows
indicate corresponding fracture location in vivo (Adapted from
[33]) B) MDA-MB-231 breast cancer injected intracranially 3
weeks prior to administration of IRDye BoneTag (shown in
red) and IRDye800CW EGF (shown in green). BoneTag has
been used to visualize the bone anatomy/structure in con-
junction with secondary optical agents speciﬁc for a primary
target (Copyright, LI-COR, Inc., used by permission).
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enzyme-activated ﬂuorescent agent hydrolyzed by several cathepsins,
preferentially Cat B. ProSense has demonstrated utility in imaging Cat
B+macrophage inﬁltration within preclinical colon cancer animal
models [51,52]. Withana et al. noninvasively evaluated the eﬃcacy of
Cat B inhibition via the small molecule inhibitor CA-074 in order to
treat metastatic breast cancer [40]. GB123 is a Cat B-speciﬁc activity-
based ﬂuorescent contrast agent (Ex./Em. 633 nm/680 nm) and was
used to evaluate expression of Cat B in vivo. Using the ﬂuorescent di-
phosphonate probe OsteoSense750, cysteine cathepsin activity was co-
registered along the spine of mice bearing breast tumors metastasized
to the bone (Fig. 4). This activity was reduced in mice treated with CA-
074 and showed decreased metastasis in lung and bone regions.
Similar contrast agents are available that contain a slightly diﬀerent
backbone or linker sequence resulting in speciﬁcity for other proteases.
Using a cleavable Cat K probe that consists of an amino acid backbone
chain functionalized with Cy5.5 ﬂuorophores through the Cat K-sensi-
tive link sequence, Kozloﬀ et al. ﬁrst demonstrated noninvasive visua-
lization of bone-degrading enzymes in models of accelerated bone loss
[53]. Cat K Fluorescent Activatable Sensor Technology (FAST) is an-
other cleavable probe speciﬁc to Cat K. Cat K 680 FAST (PerkinElmer)
was developed based on a human Cat K-cleavable sequence, a pair of
self-quenching NIR ﬂuorochromes and a pharmacokinetic modiﬁer to
confer increased blood half-life. The agent is optically quenched in its
native form, but upon cleavage by Cat K, it becomes highly ﬂuorescent
(Ex./Em. 674 nm/692 nm). Cat K FAST has shown promising results in
speciﬁc imaging of the biological activity of regions of bone resorption
and osteocytes in osteoarthritic models [54].
Matrix Metalloproteinases (MMPs) are important factors associated
with remodeling of the tumor microenvironment and local activation of
the immune system. MMPs have been implicated in mediating expres-
sion of Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL),
promoting osteolysis and metastases to the bone [55]. MMPs are also
involved in regulating angiogenesis through release of Vascular En-
dothelial Growth Factor (VEGF) and Epidermal Growth Factor (EGF)-
like factors [56]. MMPSense (Perkin Elmer) is a small molecular poly-
peptide (GPLGVRGKC) conjugated to a pegylated polylysine scaﬀold
and is ﬂuorescent upon enzymatic cleavage, predominantly from MMP
7, 9 12, and 13. This MMP probe has been used to visualize local
proteinase activity and macrophage activation in diseases like athero-
sclerosis [50] as well as osteoarthritis [57,58]. In summary, imaging
proteinase-activated ﬂuorescent probes can provide functional in-
formation on interactions between the tumor microenvironment, os-
teoclastic bone resorption and local inﬂammation.
2.3. NIR skeletal imaging techniques
In the following sections, we provide an overview on recent ad-
vances of Raman and NIR spectroscopy as well as photoacoustic to-
mography (PAT) in the imaging of bone metastases. These modalities
rely on noninvasive, label-free imaging of endogenous tissue contrast
via NIR laser excitation, allowing for real-time imaging of molecular
processes. Each of these techniques oﬀers unique information on bone
tissue not oﬀered by NIR ﬂuorescent probes. Raman spectroscopy
provides chemical information on the structure of bone such as mineral
phosphate, carbonate, matrix collagen, and bone water content. These
measurements can serve as metrics for bone fragility and density in the
context of bone metastasis and reveal how bone strength and mechanics
are aﬀected when fracturing occurs following tumor-induced osteolysis.
PAT, conversely, can oﬀer physiological information on a tumor and
its location with respect to the bone using endogenous contrast.
Because PAT imaging relies on light propagation in one direction, the
depth and shape of a tumor can be more accurately determined than
solely with NIR contrast agents. In addition, environmental changes
surrounding the tumor in the BM microenvironment can be evaluated
in real-time. Metabolic rate of oxygen consumption and lipid content
are some of the parameters that can be measured in vivo using en-
dogenous contrast. If tissue absorptivity is known, concentrations of
these endogenous chromophores can also be quantitatively assessed
and can serve as metrics for molecular processes in the context of me-
tastases. Due to weaker ultrasound scattering and unique optical ab-
sorption contrast from hemoglobin and other tissue, PAT can provide
valuable molecular information at clinically relevant depths and at high
resolution. Exogenous contrast agents in the NIR-I window speciﬁc to
the BM can further enhance this resolution.
There are still several technical limitations with NIR spectroscopy
and PAT. Because these imaging techniques rely primarily on en-
dogenous contrast, there are a number of considerations to make to
attain optimal signal. In the case of Raman spectroscopy, heterogeneity
of optical ﬂuence and competing tissue autoﬂuorescence may also
compete with Raman scattering and can hamper the interpretation of
Raman spectra in biological samples. As for PAT, spectral overlap as
well as sensitivity of diﬀerent endogenous chromophores may interfere
with image acquisition. While current eﬀorts for both forms of optical
imaging in skeletal metastases are either limited to ex vivo bone ima-
ging or to imaging of primary tumors not metastasized to the bone,
advancements in hardware design, reconstruction algorithms and novel
contrast agents are allowing these techniques to compete with tradi-
tional imaging modalities. Technical improvements in system im-
plementation and reconstruction algorithms will be key in order to
Fig. 4. In vivo imaging of Cat B activity in tumor-
burdened mice. Fluorescence spinal images of live
mice-bearing 4T1.2 breast tumors treated with vehicle
or with Cat K inhibitor CA-074 followed by adminis-
tration of the Cat B-speciﬁc ﬂuorophore GB123 and
Osteosense750. Quantitation of mean GB123 ﬂuores-
cence signal in vehicle and CA-074-treated spines with
the FMT2500 system showed decreases in Cat B ac-
tivity following inhibition (Adapted from [40]).
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improve sensitivity, including faster scanning mechanisms and higher
frequency lasers with a wide tuning range of wavelengths for real-time
functional imaging. Comprehensive spectral databases and tissue clas-
siﬁcation methodologies that can be compared with current gold
standards will be needed to validate spectroscopic datasets. Here, we
highlight both NIR spectroscopy and PAT and their potential in eval-
uating tumors metastasized to the bone.
2.3.1. NIR spectroscopy
Raman spectroscopy is a form of vibrational spectroscopy that de-
tects scattered light from chemical bonds and biological molecules upon
excitation by NIR laser light. This light interacts with low-frequency
vibrational photons, resulting in the inelastic scattered photons being
shifted in energy to values diﬀerent than that of the excitation. This
shift is measured in terms of the diﬀerence between the inverse of the
excitation and detected wavelengths (units: cm−1) and gives informa-
tion that is speciﬁc to chemical bonds. Raman spectroscopy depends on
the polarizability of a molecule and is more sensitive to homo-nuclear
bonds [59]. The resulting spectra provides a ﬁngerprint by which dif-
ferent molecular species can be identiﬁed and their relative con-
centrations evaluated based on the strength of diﬀerent peaks. Biolo-
gical tissues contain a large number of Raman-active molecules,
resulting in spectroscopic measurements that are in eﬀect a weighted
sum of spectra from all molecular species within a tissue.
Raman spectroscopy has been used to characterize bone composi-
tion in relation to bone strength and allows for analysis of intact sam-
ples in a hydrated state without additional processing of bone tissue
[59]. Phosphate, amide I and mineral carbonate are some of the most
commonly detected bonds in the bone matrix [60]. While phosphates
(∼959 cm−1) are characteristic of the HA in the bone matrix, amide I
(1616 –1720 cm−1) and mineral carbonate (1070 cm−1) are both
measures of collagen structure [61]. Ratiometric measurements of the
band intensities with respect to the bond peaks are calculated as either
a mineral/matrix, carbonate/phosphate or collagen cross-link ratio.
These ratios can be used to assess bone remodeling and compositional
trends in various bone specimens and disease models [59]. In the area
of cancer metastases, Raman spectroscopy has been used to evaluate
bone mineral content in metastasized breast and prostate cancer
models. In metastasized breast cancer, phosphate/amide I ratio as well
as carbonate/phosphate ratios increased in the bone with increasing
tumor burden and bone lesion size, suggesting an increase in mineral
density and reduction in bone toughness in the presence of tumors
(Fig. 5A) [62]. Similarly, in metastasized prostate cancer models, car-
bonate/phosphate ratios were greater in tumor-bearing bones while
carbonate/matrix ratios signiﬁcantly decreased, suggesting that the
presence of tumors elevated bone turnover rate instead of a synergetic
change with bone mineralization (Fig. 5B) [63,64]
In addition to bone mineral density and collagen, water content and
hemodynamics within the bone have been evaluated with NIR spec-
troscopy (NIRS). While NIRS has a lower resolution limit compared to
Raman due to its broader spectral features and lower intensities, NIRS
absorption bands arise from molecular vibrations of CeH, CeO, OeH
and NeH bonds, allowing for monitoring of water content, lipids, he-
moglobin and proteins [65]. These are features unattainable through
Raman spectroscopy. Water distribution in BM serves as endogenous
contrast in MRI for detecting and characterizing lesions. NIRS was
shown to have similar resolution to ultra-short echo time MRI when free
bone water as well as water-bound collagen was evaluated in cadaver
human tibiae ex vivo [66]. NIRS has also been used in the evaluation of
oxygenated and deoxygenated bone tissue in vivo [67]. In addition to
hemodynamics and water, studies have also been conducted in evalu-
ating lipid and protein content within soft tumor tissue in a variety of
cancers, primarily breast cancer. Additional information on NIRS in
cancer can be found at ref [68]. In summary, Raman and NIR spec-
troscopy have great potential in characterizing biochemical compo-
nents of bone structure and can be related to fracture risk and lesions in
the presence of metastasized tumors.
2.3.2. Photoacoustic tomography
Photoacoustic Tomography (PAT) is a hybrid imaging modality that
is based on the acoustic detection of optical absorption from biological
tissue exposed to a pulsed laser. Following absorption of light by the
tissue, the absorbed light is converted into heat, resulting in the ex-
pansion of thermoacoustic waves. Biological tissues contain several
kinds of endogenous chromophores such as hemoglobin, melanin and
lipids which have strong absorptivity when excited at the appropriate
wavelengths [69]. These endogenous contrast agents allow for mon-
itoring of physiological changes such as oxygen saturation and vascular
blood volume in association with these chromophores. Multispectral
imaging of malignant tumors has been performed within a wide variety
of preclinical and clinical studies including: breast, skin, prostate, and
ovarian. Vasculature and oxygen saturation within the tumor tissue
have been characterized for detection of angiogenesis [70]. Imai et al.
used optical-resolution photoacoustic microscopy (PAM) to non-
invasively quantify total oxygen saturation (sO2) and vascularization
during MM progression. In vivo PAM of the cerebral BM in im-
munocompromised mice, following MM cell injection, showed that MM
tumor regions had signiﬁcantly lower total sO2 concentrations and
blood vessel densities than in non-tumor aﬀected regions. This de-
monstrated both the development of hypoxia due to MM cell pro-
liferation and decreased vascularization surrounding the tumor areas
[71]. Detection of metastatic tumors as well as circulating tumor cells
(CTCs) have also been performed with PAT-based ﬂow cytometry.
Guiettez-Juarez et al. [72] and Galanzha et al. [73] both detected 1
CTC/1mL of blood in vivo and Juratli et al. [74] has shown that ma-
nipulation of tumors such as pressure, biopsy and laser treatment can
dramatically increase CTC counts and cancer metastasis.
In addition to endogenous contrast imaging, exogeneous agents
utilizing NIR dyes as well as nanoparticles have been used to enhance
the contrast of tumor tissue in vivo. Non-speciﬁc and speciﬁc contrast
agents have been designed for this purpose. NIR-absorbing dyes such as
IRDye800CW [75], AlexaFluor740 [76], and indocyanine green (ICG)
[77,78] have served as PAT contrast agents. Metal particle-based con-
trast agents, primarily gold nanoparticles, have also been used to en-
hance PAT contrast. Gold has become a metal of choice due to its high
absorption coeﬃcient, thermal conductivity, and surface plasma re-
sonance [79] and has shown concentration-dependent enhancement in
signal-to-noise ratio and resolution [80]. While PAT has yet to be ex-
tensively studied in bone cancer metastases, early eﬀorts have been
made in using PAT to enhance tumor contrast in preclinical osteo-
sarcoma models (Fig. 5C) [81,82]. PAT has also been studied in ex vivo
imaging of vasculature in bone tissue in arthritic rat models as well as
human cortical bones with high contrast and resolution [83,84]. Var-
ious conﬁgurations of pulsed laser diodes have been designed to excite
endogenous HA and hemoglobin in the NIR-I window [85]. With
multispectral imaging, in conjunction with NIR probes speciﬁc for
targets within the tumor, PAT could provide valuable insight into tumor
interactions with the bone microenvironment, speciﬁcally in relation to
changes in hemoglobin content.
2.4. Conclusions and future directions
Bone metastases is a complex process that can ultimately lead to
mortality if left untreated. It is therefore integral to understand the
complicated mechanisms underlying skeletal metastasis and to develop
better methods of monitoring therapy in vivo. Optical imaging is a
promising tool in understanding this disease's pathogenesis and its as-
sociated therapies.
In the area of NIR ﬂuorescent compounds, there are still a host of
factors that could serve as potential targets for imaging. New tracers
targeting diﬀerent molecular signatures, and therefore biologic prop-
erties of bone metastasis, will enhance knowledge of disease
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progression. Chemokines play a central role in lymphocyte traﬃcking
and homing, speciﬁcally the chemokine receptor 4 (CXCR4). Previous
studies have shown that CXCR4 plays a critical role in homing of MM
tumoral cells to the BM. Inhibition of the receptor not only prevents
migration of MM cells, but also sensitizes malignant tumor cells to
therapeutic agents [86]. Tumor Growth Factor-β (TGF-ß) and RANKL
are two prominent soluble factors involved in stimulation of pro-os-
teoclast formation [87]. RANKL activates osteoclast-mediated bone
resorption and subsequently promotes the release of matrix growth
factors such as TGF-ß, further inducing tumor growth in a positive
feedback mechanism [87]. Adipocytes are another important compo-
nent in the BM environment and in bone metastases. Marrow adipo-
cytes secrete factors that have profound eﬀects on the BM niche, in-
ﬂammation, and homing of tumor cells to the microenvironment [1].
Several receptors such as FABP4 and acetate have been identiﬁed in
promoting tumor growth and could serve as potential targets for non-
invasive imaging in preclinical animal models.
While NIR ﬂuorescence oﬀers valuable functional information in
preclinical animal models, there is limited translatability for non-
invasive skeletal imaging in humans due to the high tissue attenuation
of bone. NIR spectroscopy and PAT have emerged as potential non-
invasive imaging modalities for cancer imaging. Due to the reduced
tissue autoﬂuorescence and lower tissue scattering observed in this
wavelength spectrum, both imaging modalities have the potential for
translation into humans. While Raman spectroscopy and PAT have not
been studied in the context of bone metastatic models, these modalities
have entered the clinic for imaging of primary tumors in humans.
Jermyn et al. demonstrate the use of Raman spectroscopy in distin-
guishing cancer masses in late stage gliomablastoma patients [88]. This
Raman-based probe, through excitation of diﬀerent molecular species
such as DNA and cholesterol, enabled detection of previously un-
detectable diﬀusely invasive brain cancer cells at cellular resolution in
patients. Wang et al. demonstrated the ﬁrst use of PAT, in combination
with CT, to noninvasively image primary breast tumors in breast cancer
patients [89]. Using endogenous hemoglobin, the authors were able to
distinguish, at high spatiotemporal resolution, breast tumor by de-
tailing tumor associated angiogenesis without the need for ionizing
radiation or exogenous contrast agents. Limitations in the clinical
translatability of these techniques will primarily involve pushing the
depth penetration of these optical technologies further to overcome the
high tissue attenuation of bone and surrounding heterogeneous tissue
such as muscle and fat. With advances in higher frequency laser in-
strumentation, probe design and reconstruction algorithms, and in
combination with ultrasound and CT, both imaging modalities have
Fig. 5. Raman spectroscopy and photoacoustic tomographic imaging allow for label-free imaging in primary and metastasized bone cancer models. A)
Representative Raman spectra acquired from metastatic cancer-aﬀected femurs and spines. Spectra (normalized to PO43− v1 peak) were acquired from week 0 control
group (blue tracings) and 5 weeks after tumor inoculation (red tracings). The solid lines represent the mean spectrum of each sample group with associated shadings
representing±1 standard deviations (SD). The distinctive Raman peaks at 958, 1004, 1070, 1250, and 1450 cm−1 suggest changes in carbonate substitution, overall
mineralization as well as crystallinity increases in tumor-bearing bones [62] – Published by The Royal Society of Chemistry. B) representative Raman spectra of
spines in control mice (healthy) and mice inoculated with HeLa cervical or Ace-1 prostate cancer cell lines producing osteolytic or mixed (osteolytic and osteoblastic)
metastases, respectively (Adapted from [63]). C) Noninvasive in vivo photoacoustic imaging of osteosarcoma in a rat leg between 5 and 15 days after tumor
inoculation. Arrows show tumor suspicious areas. Histological images of a cross section of the rat leg 15 days after imaging show tumor suspicious area (Adapted
from [81]).
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great potential towards noninvasive imaging of bone metastases in
humans.
In conclusion, optical imaging is an important tool for evaluating
disease progression and response monitoring in preclinical models.
Various imaging approaches in the NIR-I window have been developed
to detect molecular processes involved in bone metastases and in re-
lation to the bone and its microenvironment. Each technique has its
own unique advantages and disadvantages for revealing fundamental
biological mechanisms involved in these processes and how therapies
can alter these mechanisms. In combination with ultrasound, CT, PET,
SPECT and MRI, optical imaging is beginning to see rapid clinical
translation and is enabling real-time assessment of tumor growth and
stromal interactions on a functional, structural and molecular level. The
beneﬁts of these tools in the context of bone metastases make further
investigation in this ﬁeld worthwhile and needed.
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